Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randolph Marks

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Interactive Cardiovascular and Thoracic Surgery|July 7, 2010
Primary cardiac synovial sarcomaMuhammad Talukder, Lyle Joyce, Randolph Marks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2004
Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?Tait D Shanafelt, Charles Loprinzi, Randolph Marks, et al.
Nutrition and Cancer|March 8, 2005
Exploring vitamin and mineral supplementation and purported clinical effects in patients with small cell lung cancer: results from the Mayo Clinic lung cancer cohortAminah Jatoi, Brent A Williams, Randolph Marks, et al.
Lung Cancer (Amsterdam, Netherlands)|June 14, 2005
Is voluntary vitamin and mineral supplementation associated with better outcome in non-small cell lung cancer patients? Results from the Mayo Clinic lung cancer cohortAminah Jatoi, Brent Williams, Frank Nichols, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood MarkersDong Xie, Randolph Marks, Mingrui Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|June 25, 2014
A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621Julian R Molina, Nathan R Foster, Thanyanan Reungwetwattana, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2005
Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institutionKarin F Giordano, Aminah Jatoi, Alex A Adjei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancerAlex A Adjei, Julian R Molina, Sumithra J Mandrekar, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|January 3, 2018
Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markersDong Xie, Mark S Allen, Randolph Marks, et al.
Investigational New Drugs|July 27, 2013
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignanciesShaji K Kumar, James Jett, Randolph Marks, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Interactive Cardiovascular and Thoracic Surgery|July 7, 2010
Primary cardiac synovial sarcomaMuhammad Talukder, Lyle Joyce, Randolph Marks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2004
Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?Tait D Shanafelt, Charles Loprinzi, Randolph Marks, et al.
Nutrition and Cancer|March 8, 2005
Exploring vitamin and mineral supplementation and purported clinical effects in patients with small cell lung cancer: results from the Mayo Clinic lung cancer cohortAminah Jatoi, Brent A Williams, Randolph Marks, et al.
Lung Cancer (Amsterdam, Netherlands)|June 14, 2005
Is voluntary vitamin and mineral supplementation associated with better outcome in non-small cell lung cancer patients? Results from the Mayo Clinic lung cancer cohortAminah Jatoi, Brent Williams, Frank Nichols, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood MarkersDong Xie, Randolph Marks, Mingrui Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|June 25, 2014
A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621Julian R Molina, Nathan R Foster, Thanyanan Reungwetwattana, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2005
Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institutionKarin F Giordano, Aminah Jatoi, Alex A Adjei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancerAlex A Adjei, Julian R Molina, Sumithra J Mandrekar, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|January 3, 2018
Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markersDong Xie, Mark S Allen, Randolph Marks, et al.
Investigational New Drugs|July 27, 2013
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignanciesShaji K Kumar, James Jett, Randolph Marks, et al.
Pageof 2